In addition, co-administration of pablizumab (an PD-1 inhibitor) with CAR-T cells has also been found to restore the production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) which can further facilitate anti-cancer immunity [107]. Here, TNF is linked to cancer.